| Target Price | CHF229.50 |
| Price | CHF152.35 |
| Potential | 50.64% |
| Number of Estimates | 23 |
| 23 Analysts have issued a price target Sika 2026 . The average Sika target price is CHF229.50. This is 50.64% higher than the current stock price. The highest price target is CHF367.50 141.22% , the lowest is CHF161.60 6.07% . | |
| A rating was issued by 28 analysts: 19 Analysts recommend Sika to buy, 5 to hold and 4 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Sika stock has an average upside potential 2026 of 50.64% . Most analysts recommend the Sika stock at Purchase. |
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion CHF | 11.76 | 11.64 |
| 4.67% | 1.05% | |
| EBITDA Margin | 19.29% | 19.65% |
| 1.87% | 1.85% |
24 Analysts have issued a sales forecast Sika 2025 . The average Sika sales estimate is CHF11.6b . This is 19.77% lower than the revenue of the last 12 months(TTM). The highest sales forecast is CHF12.9b 11.08% , the lowest is CHF11.0b 24.27% .
This results in the following potential growth metrics:
| 2024 | CHF11.8b | 4.67% |
|---|---|---|
| 2025 | CHF11.6b | 1.05% |
| 2026 | CHF12.0b | 2.69% |
| 2027 | CHF12.6b | 5.05% |
| 2028 | CHF13.8b | 9.66% |
| 2029 | CHF14.3b | 3.54% |
| 2030 | CHF15.4b | 7.88% |
| 2031 | CHF17.2b | 12.07% |
| 2032 | CHF18.2b | 5.42% |
23 Analysts have issued an Sika EBITDA forecast 2025. The average Sika EBITDA estimate is CHF2.3b . This is 18.94% lower than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is CHF2.4b 14.22% , the lowest is CHF2.2b 23.37% .
This results in the following potential growth metrics and future EBITDA Margins:
| 2024 | CHF2.3b | 6.63% |
|---|---|---|
| 2025 | CHF2.3b | 0.77% |
| 2026 | CHF2.5b | 7.65% |
| 2027 | CHF2.7b | 8.37% |
| 2028 | CHF2.9b | 9.56% |
| 2029 | CHF2.9b | 0.62% |
| 2030 | CHF3.7b | 29.05% |
| 2024 | 19.29% | 1.87% |
|---|---|---|
| 2025 | 19.65% | 1.85% |
| 2026 | 20.60% | 4.83% |
| 2027 | 21.25% | 3.16% |
| 2028 | 21.23% | 0.09% |
| 2029 | 20.38% | 4.00% |
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share CHF | 7.76 | 7.57 |
| 17.22% | 2.45% | |
| P/E | 20.13 |
24 Analysts have issued a Sika forecast for earnings per share. The average Sika EPS is CHF7.57 . This is 58.04% higher than earnings per share in the financial year 2024. The highest EPS forecast is CHF10.92 127.97% , the lowest is CHF5.89 22.96% .
This results in the following potential growth metrics and future valuations:
| 2024 | CHF7.76 | 17.22% |
|---|---|---|
| 2025 | CHF7.57 | 2.45% |
| 2026 | CHF8.35 | 10.30% |
| 2027 | CHF9.20 | 10.18% |
| 2028 | CHF10.66 | 15.87% |
| 2029 | CHF10.36 | 2.81% |
| Current | 31.81 | 28.19% |
|---|---|---|
| 2025 | 20.13 | 36.71% |
| 2026 | 18.25 | 9.34% |
| 2027 | 16.57 | 9.21% |
| 2028 | 14.29 | 13.76% |
| 2029 | 14.71 | 2.94% |
| Analyst | Rating | Action | Date |
|---|---|---|---|
| JEFFERIES |
Buy
➜
Buy
|
Unchanged | Aug 07 2025 |
| BERENBERG |
Buy
➜
Buy
|
Unchanged | Jul 31 2025 |
| ODDO BHF |
Buy
➜
Buy
|
Unchanged | Jul 30 2025 |
| BERENBERG |
Buy
➜
Buy
|
Unchanged | Jul 10 2025 |
| BERENBERG |
Buy
➜
Buy
|
Unchanged | Jul 09 2025 |
| ODDO BHF |
Buy
➜
Buy
|
Unchanged | Jul 04 2025 |
| JEFFERIES |
Buy
➜
Buy
|
Unchanged | Jul 04 2025 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
JEFFERIES:
Buy
➜
Buy
|
Aug 07 2025 |
|
Unchanged
BERENBERG:
Buy
➜
Buy
|
Jul 31 2025 |
|
Unchanged
ODDO BHF:
Buy
➜
Buy
|
Jul 30 2025 |
|
Unchanged
BERENBERG:
Buy
➜
Buy
|
Jul 10 2025 |
|
Unchanged
BERENBERG:
Buy
➜
Buy
|
Jul 09 2025 |
|
Unchanged
ODDO BHF:
Buy
➜
Buy
|
Jul 04 2025 |
|
Unchanged
JEFFERIES:
Buy
➜
Buy
|
Jul 04 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


